scholarly journals Expression of the visinin-like protein-1 in non-small cell lung carcinoma distinguishes squamous cell lung carcinoma from adenocarcinoma.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Squamous Cell ◽  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
The United States ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma ◽  
Lung Carcinomas ◽  
Treatment Regimens ◽  
Tumor Expression

Non-small cell lung cancer, classified as adenocarcinomas or squamous cell lung carcinomas, is the major cause of cancer death in the United States and worldwide (1). To understand the most significant transcriptional differences between adenocarcinomas and squamous cell lung carcinomas, we mined published microarray data from two separate studies (2, 3). We identified visinin-like protein-1 (VSNL1) as a distinguishing transcriptional feature of squamous cell lung carcinomas, suggesting the biology of VSNL1 may be relevant to the pathways critical for the development or maintenance of squamous cell lung carcinomas but not of adenocarcinomas. VSNL1 expression was significantly correlated with prognosis of patients with NSCLC, as patients with low tumor expression of VSNL1 possessed significantly longer median overall survival than those with high tumor expression of VSNL1. These analyses will also provide novel tools for diagnostic approaches and for guidance of treatment regimens for a cancer with dismal outlook.

scholarly journals Expression of desmocollin 3 in non-small cell lung carcinoma distinguishes squamous cell lung carcinoma from adenocarcinoma.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Squamous Cell ◽  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
The United States ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma ◽  
Lung Carcinomas ◽  
Treatment Regimens ◽  
Tumor Expression

Non-small cell lung cancer, classified as adenocarcinomas or squamous cell lung carcinomas, is the major cause of cancer death in the United States and worldwide (1). To understand the most significant transcriptional differences between adenocarcinomas and squamous cell lung carcinomas, we mined published microarray data from two separate studies (2, 3). We identified desmocollin 3 (DSC3) as a distinguishing transcriptional feature of squamous cell lung carcinomas, suggesting the biology of DSC3 may be relevant to the pathways critical for the development or maintenance of squamous cell lung carcinomas but not of adenocarcinomas. DSC3 expression was significantly correlated with prognosis of patients with NSCLC, as patients with low tumor expression of DSC3 possessed significantly longer median overall survival than those with high tumor expression of DSC3. These analyses will also provide novel tools for diagnostic approaches and for guidance of treatment regimens for a cancer with dismal outlook.

scholarly journals Expression of ceramide synthase 3 in non-small cell lung carcinoma distinguishes squamous cell lung carcinoma from adenocarcinoma.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Squamous Cell ◽  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
The United States ◽  
Small Cell ◽  
Ceramide Synthase ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma ◽  
Lung Carcinomas ◽  
Tumor Expression

Non-small cell lung cancer, classified as adenocarcinomas or squamous cell lung carcinomas, is the major cause of cancer death in the United States and worldwide (1). To understand the most significant transcriptional differences between adenocarcinomas and squamous cell lung carcinomas, we mined published microarray data from two separate studies (2, 3). We identified ceramide synthase 3 (CERS3) as a distinguishing transcriptional feature of squamous cell lung carcinomas, suggesting the biology of CERS3 may be relevant to the pathways critical for the development or maintenance of squamous cell lung carcinomas but not of adenocarcinomas. CERS3 expression was significantly correlated with prognosis of patients with NSCLC, as patients with low tumor expression of CERS3 possessed significantly longer median overall survival than those with high tumor expression of CERS3. These analyses will also provide novel tools for diagnostic approaches and for guidance of treatment regimens for a cancer with dismal outlook.

scholarly journals Expression of desmoglein 3 in non-small cell lung carcinoma distinguishes squamous cell lung carcinoma from adenocarcinoma.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Squamous Cell ◽  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
The United States ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma ◽  
Lung Carcinomas ◽  
Treatment Regimens ◽  
Desmoglein 3

Non-small cell lung cancer, classified as adenocarcinomas or squamous cell lung carcinomas, is the major cause of cancer death in the United States and worldwide (1). To understand the most significant transcriptional differences between adenocarcinomas and squamous cell lung carcinomas, we mined published microarray data from two separate studies (2, 3). We identified desmoglein 3 (DSG3) as a distinguishing transcriptional feature of squamous cell lung carcinomas, suggesting the biology of DSG3 may be relevant to the pathways critical for the development or maintenance of squamous cell lung carcinomas but not of adenocarcinomas. DSG3 expression was significantly correlated with prognosis of patients with NSCLC, with patients expressing low levels of DSG3 possessing significantly longer median overall survival. These analyses will also provide novel tools for diagnostic approaches and for guidance of treatment regimens for a cancer with dismal outlook.

scholarly journals Expression of the interferon regulatory factor 6 in non-small cell lung carcinoma distinguishes squamous cell lung carcinoma from adenocarcinoma.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Squamous Cell ◽  
Lung Carcinoma ◽  
Interferon Regulatory Factor ◽  
Small Cell ◽  
Regulatory Factor ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma ◽  
Lung Carcinomas ◽  
Interferon Regulatory Factor 6 ◽  
Tumor Expression

Non-small cell lung cancer, classified as adenocarcinomas or squamous cell lung carcinomas, is the major cause of cancer death in the United States and worldwide (1). To understand the most significant transcriptional differences between adenocarcinomas and squamous cell lung carcinomas, we mined published microarray data from two separate studies (2, 3). We identified interferon regulatory factor 6 (IRF6) as a distinguishing transcriptional feature of squamous cell lung carcinomas, suggesting the biology of IRF6 may be relevant to the pathways critical for the development or maintenance of squamous cell lung carcinomas but not of adenocarcinomas. IRF6 expression was significantly correlated with prognosis of patients with NSCLC, as patients with low tumor expression of IRF6 possessed significantly longer median overall survival than those with high tumor expression of IRF6. These analyses will also provide novel tools for diagnostic approaches and for guidance of treatment regimens for a cancer with dismal outlook.

scholarly journals EPID-17. ANALYSIS OF THE USE OF BEVACIZUMAB FOR THE TREATMENT OF GLIOBLASTOMA IN THE UNITED STATES

2019 ◽  
Vol 21 (Supplement_6) ◽  
pp. vi78-vi78
Author(s):  
Catherine Garcia ◽  
Holly Chitwood ◽  
Christopher Harwood ◽  
Brent Shelton ◽  
Rachael Morgan ◽  
...  
Keyword(s):  
United States ◽  
Colorectal Carcinoma ◽  
Lung Carcinoma ◽  
Randomized Clinical Trials ◽  
Small Cell Lung Carcinoma ◽  
The United States ◽  
Small Cell ◽  
Small Cell Lung ◽  
Novel Therapy ◽  
Cell Lung Carcinoma

Abstract INTRODUCTION Bevacizumab is an antibody against vascular endothelial growth factor that has been well investigated for glioblastoma, however, has limited proven efficacy. The drug has, however, demonstrated survival benefit in non-small cell lung carcinoma, renal cell carcinoma and colorectal carcinoma. We provide an overview of its use in the United States for select cancers. METHODS We queried the IQVIA database for all cases of glioblastoma diagnosed between January 2014 and June 2018 to analyze the use of bevacizumab for glioblastoma, non-small cell lung carcinoma, and colorectal carcinoma in the United States, and was compared to the standard of care for each indication (temozolomide for glioblastoma, pemetrexed for non-small cell lung carcinoma, and oxaliplatin for colorectal carcinoma). RESULTS A total of 85,351 patients were treated for glioblastoma as captured by IQVIA. Bevacizumab was prescribed in 17,958 patients, with a projected median annual total of 3,718 patients. The use of bevacizumab for glioblastoma during the study period decreased from 2014 to 2018 (p< 0.0001). The use of temozolomide has remained stable since 2014 to 2018 (p=0.49). For non-small cell lung cancer, we saw a significant decrease in the use of both bevacizumab and pemetrexed (p< 0.0001), with bevacizumab being used in less than 2% of the cases since 2017. For colorectal carcinoma, the use of bevacizumab has overall decreased with a peak use in 2016 (p< 0.0001). The use of oxaliplatin has increased (p< 0.0001). CONCLUSIONS Our findings demonstrated a decreased use of bevacizumab in oncology for three indications, likely associated with a changing role due to the benefit of novel therapy such as immunotherapy. The use of bevacizumab has decreased in glioblastoma, that may be associated to the lack of overall survival benefits in randomized clinical trials.

Comparison of Differential Diagnosis of Lung Cancer by Diffuse Weighted Imaging and Sagittal Imaging with Short Inversion Recovery Sequence

2021 ◽  
Vol 11 (3) ◽  
pp. 822-826
Author(s):  
Wei Zhang ◽  
Qingyu Cai ◽  
Guoli Wei
Keyword(s):  
Lung Cancer ◽  
Differential Diagnosis ◽  
Squamous Cell ◽  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Small Cell Lung ◽  
Recovery Sequence ◽  
Cell Lung Carcinoma ◽  
Diagnosis Of Lung Cancer

The differential diagnosis of advanced lung cancer is difficult in clinical practice. Our study aims to compare the value of diffusion weighted imaging (DWI) with short-term inversion recovery sequence (STIR) for sagittal imaging in the differential diagnosis of lung cancer. 149 patients with non-small cell lung carcinoma (NSCLC) were enrolled and underwent DWI and STIR sagittal imaging. To quantify cancer types, we evaluated the apparent diffusion coefficient (ADC) value on DWI and the contrast ratio (CRs) on sagittal imaging. The ADC values of subclasses in NSCLC were significantly higher than small cell lung carcinoma (SCLC) (p <0.01). The mean CRs were 1.59 for SCLC and 1.30 for NSCLC with a significant difference (p < 0.01). Large cell carcinomas (LCC) and adenocarcinomas have significant differences compared to small cell carcinomas (SCC) without difference between squamous cell carcinomas (p > 0.05); this is also the case for CRs. Squamous cell carcinoma and adenocarcinoma have significant differences compared to SCC without difference in LCC (p > 0.05). Qualitative evaluation of the feasible thresholds DWI and STIR showed that the thresholds were 0.9810−3 mm2/s and 1.37 respectively. The specificity and accuracy was 78.5% is 85.3% for DWI, which was significantly higher than STIR (56.3% and 61.0%). The combination of DWI and STIR sequences was superior to DWI alone with an accuracy rate of 94.3%. DWI is more helpful than STIR in differentiating SCLC and NSCLC, and their combined use can significantly improve diagnosis accuracy.

P2.02-048 Survival Correlation Between TP53 Gene and PD-L1 Tumor Expression in Resected Non-Small Cell Lung Carcinoma

2017 ◽  
Vol 12 (11) ◽  
pp. S2116-S2117
Author(s):  
J. Sui ◽  
M.Y. Teo ◽  
S. Twomey ◽  
S. Rafee ◽  
J. Mcfadden ◽  
...  
Keyword(s):  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Tp53 Gene ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma ◽  
Tumor Expression

scholarly journals The anti-apoptotic BAG3 protein is expressed in lung carcinomas and regulates small cell lung carcinoma (SCLC) tumor growth

Oncotarget ◽  
2014 ◽  
Vol 5 (16) ◽  
pp. 6846-6853 ◽  
Author(s):  
Gennaro Chiappetta ◽  
Anna Basile ◽  
Antonio Barbieri ◽  
Antonia Falco ◽  
Alessandra Rosati ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma ◽  
Lung Carcinomas
Sign in / Sign up

Export Citation Format

Share Document